Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07087821 · ClinicalTrials.gov registry record · NA
NYU Epilepsy Self-Management Study
A NA study, sponsored by NYU Langone Health.
- Recruiting
- Registry status
- NA
- Development phase
- 108
- Enrollment target
NCT07087821: Recruiting NA study, sponsored by NYU Langone Health.
NCT07087821 is a NA study that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 108 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07087821, a NA study, is actively recruiting participants, sponsored by NYU Langone Health.
- RECRUITING
- Registry status
- NA
- Development phase
- 108 participants
- Enrollment target
Study Summary
The investigators will conduct two-arm randomized controlled trials (RCTs) comparing effects of UPLIFT vs. enhanced usual care and PACES vs. enhanced usual care, respectively, on quality of life, depressive symptoms and seizures over 12 months in NYU patients with epilepsy.
Primary Outcome
RCT 1 participants only. The PHQ-9 is a 9-item assessment of depression; each item is rated on a scale from 0-3. The total score is the sum of item responses and ranges from 0-27; higher scores indicate greater levels of depression. The primary outcome is the count of participants who score less than 5 on the PHQ-9 (i.e., absence of clinically significant depressive symptoms).
Interventions
- BEHAVIORAL Enhanced Usual Care
- BEHAVIORAL UPLIFT
- BEHAVIORAL PACES
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2025-09-16 |
| Est. Completion | 2027-09-29 |
| Phase | NA |
What NCT07087821 shows while recruiting
NCT07087821 is an interventional study that assigns participants to a tested intervention. The registered 108 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 3 interventions - of which Enhanced Usual Care is the first listed.
NCT07087821 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07087821 about?
NCT07087821 is a clinical study titled "NYU Epilepsy Self-Management Study". The investigators will conduct two-arm randomized controlled trials (RCTs) comparing effects of UPLIFT vs. enhanced usual care and PACES vs. enhanced usual care, respectively, on quality of life, depressive symptoms and seizures over 12 months in NYU patients with epilepsy.
What is the current status of trial NCT07087821?
This trial is currently recruiting. It is a NA study. The enrollment target is 108 participants. The study started on 2025-09-16. Estimated completion is 2027-09-29.
What interventions are being tested in trial NCT07087821?
The interventions under investigation include: Enhanced Usual Care (BEHAVIORAL), UPLIFT (BEHAVIORAL), PACES (BEHAVIORAL).
Who is sponsoring clinical trial NCT07087821?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07087821's enrollment target sits among peer trials
108 825th of 2000 higher than 1,171 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02703207 · 108 participants · NA
Neurocognitive and Health Impact of Sleep Apnea in Elderly Veterans With Comorbid COPD
- NCT02744677 · 108 participants · NA
COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction
- NCT02781883 · 108 participants · Phase 2
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
- NCT03848663 · 108 participants · NA
Visual Remapping to Aid Reading With Field Loss
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI